Recommendations for surveillance of pulmonary dysfunction
 among childhood, adolescent, and young adult cancer survivors: a
 report from the International Late Effects of Childhood Cancer
 Guideline Harmonization Group

Maria Otth MD*, Rahel Kasteler MD*, Renée L. Mulder PhD, Jennifer Agrusa MD, Saro H.

Armenian DO, Dana Barnea MD, Prof Anne Bergeron MD, Neel S. Bhatt MD, Stephen J. Bourke

5 6

7

40

41

8 MD, Prof Louis S. Constine MD, Myrofora Goutaki PhD, Prof Daniel M. Green MD, Ulrike 9 Hennewig MD, Veronique Houdouin MD, Prof Melissa M. Hudson MD, Prof Leontien Kremer PhD, 10 Prof Philipp Latzin MD, Antony Ng PhD, Kevin C. Oeffinger MD, Christina Schindera MD, Prof 11 Roderick Skinner PhD, Grit Sommer PhD, Saumini Srinivasan MD, Dennis C. Stokes MD, Birgitta 12 Versluys MD, Nicolas Waespe MD, Daniel J. Weiner MD, Andrew C. Dietz MD°, Prof Claudia E. 13 Kuehni MD° 14 *shared first authors 15 °shared last authors 16 17 18 Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland (M • 19 Goutaki PhD, C Schindera MD, G Sommer PhD, N Waespe MD, Prof CE Kuehni MD) 20 Department of Oncology, Haematology, Immunology, Stem Cell Transplantation and Somatic • 21 Gene Therapy, University Children's Hospital Zurich, Zurich, Switzerland (M Otth MD, R 22 Kasteler MD) 23 • Pediatric Hematology-Oncology Center, Children's Hospital of Eastern Switzerland, St Gallen, Switzerland (M Otth MD, R Kasteler MD) 24 25 • Department of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland 26 (M Otth MD) 27 • Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands (RL Mulder PhD, 28 Prof LCM Kremer PhD, B Versluys MD) 29 • Department of Pediatric Hematology Oncology, C.S. Mott Children's Hospital, University of 30 Michigan, Michigan, USA (J Agrusa MD) 31 • Department of Pediatrics, City of Hope, Duarte, California, USA (SH Armenian MD) 32 Department of Hematology and Department of Oncology, Tel Aviv Sourasky Medical Center, • 33 Tel Aviv, Israel (D Barnea MD)

- Hôpitaux Universitaires de Genève, Université de Genève, Genève, Switzerland (Prof A
 Bergeron MD)
- Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA (NS Bhatt MD)
- Department of Respiratory Medicine, Royal Victoria Infirmary, Newcastle upon Tyne, United
 Kingdom (SJ Bourke MD)
 - Departments of Radiation Oncology and Pediatrics, University of Rochester Medical Center, Rochester, NY, USA (Prof LS Constine MD)
- Department of Oncology (Prof MM Hudson MD, Prof DM Green MD), Department of
 Epidemiology and Cancer Control (Prof MM Hudson MD), St Jude Children's Research
 Hospital, Memphis, TN, USA
- University Hospital of Giessen and Marburg, Pediatric Hematology and Oncology, Giessen,
 Germany (U Hennewig MD)
- 47 AP-HP, Hôpital Robert Debré, Service de Pneumopédiatrie, Paris, France (V Houdouin MD)

48 49 50	 Division of Paediatric Respiratory Medicine and Allergology, Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland (M Goutaki PhD, Prof P Latzin MD)
50	FIOLF LALZIH MD) $P_{1}(x, y) = P_{1}(x, y$
51	• Department of Paediatric Oncology, Royal Hospital for Children, Bristol, UK (A Ng PhD)
52	• Department of Community and Family Medicine, Duke University School of Medicine,
53	Durham, NC, USA (KC Oeffinger MD)
54	• Division of Pediatric Oncology/Haematology, University Children's Hospital Basel,
55	University of Basel, Basel, Switzerland (C Schindera MD)
56	• Department of Paediatric and Adolescent Haematology/ Oncology, Great North Children's
57	Hospital and Newcastle University Centre for Cancer, Newcastle upon Tyne, UK (Prof R
58	Skinner PhD)
59	• Division of Pulmonology, Department of Pediatrics, University of Tennessee Health Science
60	Center, Memphis, Tennessee, USA (S Srinivasan MD, D Stokes MD)
61	Pediatric Hematology and Oncology University Children's Hospital Bern University of Bern
62	Bern Switzerland (N Waespe MD Prof CE Kuehni MD)
63	CANSEARCH Research Platform for Paediatric Oncology and Haematology Department of
6 <i>1</i>	Pediatrics Gynecology and Obstatrics Eaculty of Medicine University of Geneva Geneva
65	Switzerland (N Waespe MD)
66	 Division of Dedictric Dulmonology University of Dittehurgh Dittehurgh DA USA (DI Wainer
67	• Division of reductic runnonology, University of Phisodegii, Phisodegii, PA, USA (DJ weiner MD)
07	
08	• Shape Therapeutics, Inc., Seattle, WA, USA (AC Dietz MD)
69	
70	
71	
72	Corresponding author:
73	Claudia E Kuehni
74	Institute of Social and Preventive Medicine
75	University of Bern
76	Bern, Switzerland
77	claudia.kuehni@unibe.ch
78	Phone: 0041 31 684 35 07
79	
80	
81	Source of support:
82	Swiss Cancer Research (grant no: KFS-4157-02-2017, KLS/KFS-4825-01-2019 and KFS-5302-02-
83	2021), Cancer League Bern, Kinderkrebshilfe Schweiz and Lung League Bern supported our study.
84	
85	
86	Keywords:
87	- Children
88	- Adolescents
89	- Young adults
90	- Survivors
91	- Childhood cancer/malignancy
92	- Late effects
93	- Pulmonary dysfunction
94	- Lung disease
95	- Respiratory
96	- Surveillance
97	- Lung Function
98	
99	

100 Abbreviations

101	ATS	American Thoracic Society
102	CAYA	Childhood Adolescent and Young Adult
103	COG	Childrens' Oncology Group
104	DCOG	Dutch Childrens' Oncology Group
105	DLCO	Diffusion capacity for carbon-monoxide
106	ERS	European Respiratory Society
107	FEV1	Forced expiratory volume in the first second
108	FVC	Forced vital capacity
109	GLI	Global Lung Initiative
110	GRADE	Grading of Recommendations, Assessment, Development and Evaluation
111	GvHD	Graft versus Host Disease
112	HSCT	Haematopoietic Stem Cell Transplantation
113	IGHG	International Guideline Harmonization Group
114	LTFU	Long-term follow-up
115	MEF25-75%	Maximal expiratory flow between 25% and 75% of the FVC
116	PFT	Pulmonary function testing
117	PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses
118	RV	Residual volume
119	TBI	Total Body Irradiation
120	TLC	Total lung capacity
121	UKCCLG	United Kingdom Children's Cancer and Leukaemia Group

122 ABSTRACT

123 Childhood, adolescent, and young adult (CAYA) cancer survivors are at risk of pulmonary 124 dysfunction. Current follow-up care guidelines are discordant. Therefore, the International Late 125 Effects of Childhood Cancer Guideline Harmonization Group established and convened a panel of 33 126 experts to develop evidence-based surveillance guidelines. We critically reviewed available evidence 127 regarding risk factors for pulmonary dysfunction, types of pulmonary function testing, and timings of 128 surveillance, then we formulated our recommendations. We recommend that CAYA cancer survivors 129 and healthcare providers are aware of reduced pulmonary function risks and pay vigilant attention to 130 potential symptoms of pulmonary dysfunction, especially among survivors treated with allogeneic 131 haematopoietic stem cell transplantation, thoracic radiotherapy, and thoracic surgery. Based on 132 existing limited evidence, our panel currently recommends pulmonary function testing only for 133 symptomatic survivors. Since scarce existing evidence informs our recommendation, we highlight the 134 need for prospective collaborative studies to address pulmonary function knowledge gaps among 135 CAYA cancer survivors.

136 INTRODUCTION

137 Children, adolescents, and young adults (CAYA) diagnosed with cancer are at risk for pulmonary 138 dysfunction and death from pulmonary conditions years to decades after completing treatment (1-5). 139 Treatment modalities previously defined as lung-toxic include chemotherapeutic agents, such as 140 busulfan, bleomycin, carmustine, and lomustine, and thoracic radiotherapy, thoracic surgery, and 141 allogeneic haematopoietic stem cell transplantation (HSCT) (6, 7). Pathophysiological mechanisms of 142 pulmonary damage include oxidative stress from lung-toxic chemotherapeutics, free radical formation 143 during radiotherapy, and transplant-specific pulmonary complications, such as idiopathic pneumonia 144 syndrome or bronchiolitis obliterans (7-9). Free radicals injure type II pneumocytes, resulting in 145 decreased proliferative capacity, less surfactant production, and ultimately reduced lung compliance 146 (10). Activations of an inflammatory cascade and changes in endothelial cells of surrounding 147 vasculature result in leakage of proteins and inflammatory cells into alveoli (10). Such inflammation is 148 commonly the final path of different pathophysiological mechanisms which can either resolve or 149 progress to fibrotic changes in alveolar septa, causing restrictive impairments. Surgical removal of 150 parts of the lung or chest wall as part of cancer therapy reduces lung volumes and causes restrictive 151 changes.

152 Symptomatic pulmonary dysfunction presents with chronic cough or dyspnea, especially on exertion. 153 With large pulmonary functional reserve, dyspnea may not be noticed until a substantial decline in 154 pulmonary function has occurred. Pulmonary function testing (PFT) detects pulmonary dysfunction 155 before symptoms arise. Commonly used PFT include spirometry, body plethysmography, and 156 measurement of diffusion capacity for carbon-monoxide (DLCO). Spirometry and body 157 plethysmography mainly assess changes in larger airways. Examinations detecting changes in lung 158 periphery or inhomogeneous ventilation, such as washout tests, are used to answer research questions, 159 yet remain unintroduced into routine clinical care (11). Among CAYA cancer survivors exposed to 160 lung-toxic treatments, obstructive changes have been reported in up to 4%, restrictive disease 24%, 161 and diffusion capacity impairment 49% (1, 2). Proportions are even higher among certain sub-groups 162 of CAYA cancer survivors, such as following HSCT (12).

163 Since long-term CAYA cancer survivor numbers constantly increase from diagnostic, risk 164 stratification, and treatment strategy advances, long-term CAYA cancer survivor surveillance is a high 165 priority (13). Awareness of the risk of late effects from cancers or treatments led to the development of 166 different long-term follow-up (LTFU) guidelines, such as those from the Children's Oncology Group 167 (COG), the Dutch Childhood Oncology Group (DCOG), and from the United Kingdom Children's 168 Cancer and Leukaemia Group (UKCCLG) (14-16). Although COG, DCOG, and UKCCLG guidelines 169 recommend screening for pulmonary dysfunction, they are discordant regarding indication, timing of 170 initiation, frequency, and screening method. The International Late Effects of Childhood Cancer 171 Guideline Harmonization Group (IGHG) surveillance guidelines develop internationally harmonised 172 and implementable recommendations based on evidence from existing literature and international 173 expert consensus when evidence is unavailable (17). In this current IGHG initiative, we specifically 174 define which CAYA cancer survivors likely benefit from screening for pulmonary dysfunction and 175 when and how screening should be performed. We also further highlight limitations of the current 176 evidence informing surveillance recommendations for pulmonary dysfunction and knowledge gaps to 177 address in future research.

178 METHODS

Methodology of International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) and formulating key questions

Information about methods used to formulate IGHG recommendations was published previously (18).
For our current recommendation, we organised a guideline panel of 33 members—representing COG,
DCOG, UKCCLG, the Pan-European Network for Care of Survivors after Childhood and Adolescent
Cancer (PanCare)—and pulmonary health and late effects experts from various medical specialties:
paediatric oncology and haematology; paediatric and adult pulmonology; radiation oncology;
epidemiology; and guideline experts (Appendix A) (19-21).

187 IGHG's approach to formulating recommendations involves answering five key questions: 1) "Who 188 needs surveillance?" 2) "What surveillance modality should be used?" 3) "At what frequency should 189 surveillance be performed?" 4) "When should surveillance be initiated?" and 5) "What should be done 190 when abnormalities are found?" Based on our preliminary literature search and a resulting absence of 191 data, we performed the systematic literature search for only question 1) "Who needs surveillance?" 192 and used expert opinions from paediatric and adult pulmonologists for questions 2–5. We did not use 193 guidelines for surveillance of other pulmonary diseases, such as idiopathic interstitial pneumonitis or 194 chronic obstructive pulmonary disease, due to different underlying pathophysiological mechanisms. 195 Notably, guidelines for other diseases start with symptomatic patients diagnosed with specific 196 pulmonary diseases, which differs from our population of interest—asymptomatic CAYA cancer 197 survivors at risk of developing pulmonary problems.

198 Comparing existing guidelines and formulating clinical questions

First, we separately compared COG, DCOG, Scottish Intercollegiate Guidelines Network, and UKCCLG recommendations for each of the five key questions (15, 16, 19, 22). For the key question, "What should be done when abnormalities are found?" we also included vaccination and lifestyle factors. For the key question "Who needs surveillance?" we subsequently formulated 11 clinical questions and sub-questions to strengthen concordant recommendations and find consensus for discordant recommendations (Appendix B).

205 We used the PICO-framework to formulate clinical questions (23). Our *population* of interest included 206 CAYA cancer survivors-defined by at least 50% of survivors diagnosed before age 30-who 207 completed cancer treatment at least two years previously. We included potentially lung-toxic treatment 208 modalities (selected chemotherapeutic agents, thoracic radiotherapy, thoracic surgery, and allogeneic 209 HSCT) and tobacco exposure as interventions. We also included all chemotherapeutic agents 210 mentioned in current LTFU guidelines as risk factors for pulmonary dysfunction (bleomycin, busulfan, 211 and nitrosoureas [lomustine and carmustine]). Based on expert opinion, we additionally included 212 treatment with cyclophosphamide, gemcitabine, and methotrexate. Comparators were considered 213 during data extraction and differed between studies according to study design, such as non-exposed 214 survivors, survivors exposed to lower chemotherapeutic doses, or community controls. Our outcome 215 of interest was pulmonary dysfunction assessed by PFT. We focused on this single outcome because 216 our preliminary literature search showed that other commonly reported clinical endpoints-in 217 particular survivor-reported symptoms or clinician-reported diagnoses-had been assessed and 218 reported heterogeneously and had the risk of subjectivity, such as different definitions of chronic

cough or dyspnea (24-28). We categorised pulmonary dysfunction into four groups: obstruction (by FEV1, FEV1/FVC, MEF25–75%); restriction (by TLC, FVC); hyperinflation (by RV, RV/TLC); and diffusion capacity impairment (by DLCO). Although clinically relevant hyperinflation should be interpreted together with obstruction, we defined hyperinflation as a separate pulmonary outcome since it was defined as such in included studies.

224 Systematic literature search on "Who needs surveillance?"

225 We conducted our first systematic literature search in accordance with the preferred reporting items 226 for systematic reviews and meta-analyses (PRISMA) guidelines restricted to PubMed and Ovid in 227 November 2016 with updates in June 2019; December 2020; June 2022; and April 2023 (29). We 228 developed our search strategy based on 11 clinical questions and five concepts: cancer diagnosis, 229 population of CAYA cancer survivors, potential lung-toxic treatment modalities, pulmonary 230 outcomes, and late effects (Appendix C). The inclusion criteria were given through the PICO-231 framework. We also excluded studies with fewer than 20 participants and studies only assessing 232 prevalence of pulmonary dysfunction without measuring effect sizes of associations between 233 exposures and pulmonary dysfunction (Appendix D).

Guideline panel members screened titles, abstracts, and full-texts. Two authors independently screened each study. Coordinators (MO, RK) resolved discrepancies. We extracted data from each study and entered it into evidence summary tables (Appendix E); separately performed risk of bias assessments for each study (Appendix F); and completed overall quality assessments of available evidence for each clinical question, according to the GRADE criteria (Appendix G) (18, 30). Each eligible study could contribute to answering more than one clinical question. For our overall conclusion of evidence, we summarised findings by type of pulmonary dysfunction (Appendix H).

241 Expert consensus on surveillance modality, start and frequency of screening, and procedures in

242 case of pulmonary dysfunction

For questions about surveillance modality, start and frequency of screening, and procedures in cases of pulmonary dysfunction (key questions $2\Box 5$), we held numerous meetings with paediatric and adult pulmonologists and guideline development experts. We formulated suggestions based on initial 246 meetings, which we then discussed with guideline panel members until reaching consensus through an

247 iterative approach with successive revisions and implementing suggestions from all panel members.

248

249 Translating evidence into recommendations

We assessed evidence and information we gathered from our systematic literature search and expert consensus within the evidence-to-decision framework—it weighs the impact of screening by estimating benefits and harms, resources and costs, impact on health inequities, acceptability, and feasibility. Through panel discussions, we achieved consensus for final recommendations, which we subsequently discussed with additional experts, including oncologists and survivors (Appendix A).

255 **RESULTS**

256 Comparison with existing guidelines

257 Comparing existing guidelines revealed relevant discordance (Appendix I). Since the Scottish 258 guideline omitted recommendations for pulmonary dysfunction, we excluded it (22). The remaining 259 three guidelines considered CAYA cancer survivors at risk for pulmonary dysfunction after exposure 260 to bleomycin, busulfan, nitrosoureas, thoracic radiotherapy, or thoracic surgery. Practical details 261 revealed discordances, including cut-off doses for chemotherapeutic agents or thoracic radiotherapy; 262 radiation volume; age at treatment; and additional risk factors, such as renal dysfunction and 263 pulmonary infection. All three guidelines recommended PFT, yet did not specify tests. We found no 264 concordance for screening frequency and starting screening with five and ten years after diagnosis in 265 the Dutch guideline; two years after completion of treatment in the COG guideline; and end of 266 treatment in the UK guideline. Guidelines agreed about referring CAYA cancer survivors to 267 pulmonologists in cases of pulmonary dysfunction; alerting anaesthetists about previous bleomycin 268 treatment; advising survivors not to smoke; and considering pneumococcal and influenza 269 immunisation (Appendix I).

270 General results from systematic literature search

Our systematic literature search identified 9284 studies. We assessed 704 full-texts for eligibility; 26 studies fulfilled inclusion criteria (Figure 1, Table 1) (1-3, 31-53). Reasons for excluding full-texts mainly included 1) assessing outcomes other than pulmonary function by PFT (n=186); 2) including

274 non-CAYA cancer survivors (n=164); and 3) assessing outcomes fewer than two years after 275 completing treatment (n=91). Most studies (n=12) included CAYA survivors of different cancer types; 276 followed by studies on leukaemia (n=7), lymphoma (n=4), and brain tumors, neuroblastoma, and 277 osteosarcoma with one study each. Appendix J contains key characteristics and our summary of 278 evidence for each included study; Appendix K presents our evidence assessment summary and quality 279 of data contributing to recommendations per clinical question. Quality of evidence was very low or 280 low for most clinical questions (Table 2). We summarise primary reasons for downgrading the quality 281 of evidence in Table 3 and provide more detail in Appendix K.

282 Evidence on risk factors for pulmonary dysfunction among CAYA cancer survivors

283 We identified seven studies examining allogeneic HSCT as a risk factor for pulmonary dysfunction 284 (31-37); 13 studies for thoracic radiotherapy (1-3, 31, 38, 40, 45-48, 50-52); five studies for thoracic 285 surgery (1, 31, 38-40); between one and eight studies for selected chemotherapeutic agents 286 (bleomycin, busulfan, nitrosoureas, cyclophosphamide, methotrexate); no studies for gemcitabine; and 287 six studies for tobacco exposure (2, 40, 41, 43-45) (Table 2, Appendix K). For busulfan and 288 nitrosoureas, only one study of very low quality was available; it provided insufficient evidence to 289 decide whether these agents significantly impact pulmonary function (2). Four studies of low to very 290 low quality of evidence assessed pulmonary function after cyclophosphamide-containing treatment (1, 291 42, 46, 47). Studies examining effects from active tobacco smoking showed contradictory results (2, 292 41, 43-45). No studies examined impact from passive tobacco smoking or cannabis use. Our clinical 293 questions and sub-questions aimed to investigate impact from exposure versus non-exposure and also 294 impact from different dose levels; age at exposure; chronic graft versus host disease; infections; and 295 total body irradiation among individuals treated with HSCT (Appendix B). Between one and four 296 studies examined impact from different cyclophosphamide, methotrexate, and bleomycin doses; yet no 297 studies were available for different doses of nitrosoureas and busulfan. Seven studies examined the 298 impact of age at treatment with HSCT and radiotherapy.

Overall, we identified several potential sources of bias and methodological issues in most studies (Table 3). Study design was retrospective in more than half (n=14), increasing risks of bias and nonstandardised measurements. Half of the studies did not describe original population sizes from where

302 they selected participants at risk. This makes it uncertain if results are internally and externally 303 representative and can be extrapolated for the entire population of CAYA cancer survivors. Only half 304 of the studies described how they performed pulmonary function testing, such as by implementing the 305 joint European Respiratory Society (ERS)-American Thoracic Society (ATS) recommendations. Even 306 though most studies (74%) reported reference values used to standardize CAYA cancer survivor PFT 307 results, studies used 22 different sources of reference values-with up to ten different sources in one 308 study (47). Only two studies used internationally recommended all-age reference values from the 309 Global Lung Initiative (GLI) (3, 52). Cut-off value definitions, such as for restrictive disease, were 310 inconsistent, which made PFT results difficult to interpret and impossible to compare between studies 311 and age groups. Additionally, findings from different studies on the same exposure were frequently 312 inconsistent or contradictory, such as with bleomycin (31, 38, 39). Inconsistent and contradictory 313 aspects precluded analysing quantitatively and interpreting findings, such as a meta-analysis; 314 prevented formulation of recommendations for specific pulmonary function abnormalities, such as 315 obstructive, restrictive, and diffusion impairment; confounded analysis of effects of specific 316 chemotherapeutic agents on pulmonary function; or prevented definition of cut-off doses for 317 chemotherapeutics or radiotherapy. However, studies we examined provided some evidence CAYA 318 cancer survivors treated with allogeneic HSCT, thoracic radiotherapy, and thoracic surgery are at risk 319 for pulmonary dysfunction as measured by PFT.

320 Translating evidence and expert consensus into recommendations

321 Asymptomatic CAYA cancer survivors

322 Our panel concluded evidence was insufficient for recommending routine PFT for asymptomatic 323 CAYA cancer survivors at present (Appendix L, Table 4). The current evidence is low quality with 324 risks of participation bias and cannot be translated to represent the wider general situation in 325 asymptomatic CAYA cancer survivors. Such factors are essential for formulating clear 326 recommendations. For exposures with evidence of impacting pulmonary function, there is currently no 327 effective intervention that reverses or delays pulmonary disease progression among asymptomatic 328 survivors. Therefore, risk-benefit-assessments do not favour screening now. However, since extensive 329 evidence shows smoking presents harmful effects on pulmonary health among the general population,

11

330 our panel agreed about counselling CAYA cancer survivors not to smoke. The panel further 331 recommended vaccinations for CAYA cancer survivors at risk for pulmonary-related pathogens, as 332 appropriate for other vulnerable populations (Table 4). Influenza vaccination is recommended based 333 on concordance between existing guidelines. Based on local or national recommendations for 334 populations with increased vulnerability of pulmonary disease, such as pneumococcus and SARS-335 CoV-2, the panel recommended considering additional vaccinations against bacteria or viruses. All 336 three LTFU care guidelines mentioned informing anaesthetists about previous bleomycin treatment, 337 yet without further information or support from included studies; our additional search showed 338 contradictory findings (54, 55).

339 Symptomatic CAYA cancer survivors

340 For symptomatic CAYA cancer survivors—especially among those treated with allogeneic HSCT, 341 thoracic radiotherapy, and thoracic surgery—our panel agreed upon readily performing PFT with 342 results evaluated by pulmonologists experienced with CAYA cancer populations. Health care 343 professionals and CAYA cancer survivors should heed symptoms, such as chronic cough, chest 344 tightness, dyspnoea, wheezing, or exercise intolerance. Consideration of differential diagnoses, such as 345 cardiac dysfunction, should guide selection of appropriate investigations. Pulmonologists from our 346 guideline panel recommended spirometry, body plethysmography, and DLCO measurements wherever 347 possible. Breath washout tests can additionally be performed if available. Fractional exhaled nitric 348 oxide, bronchodilator reversibility tests, or other specific investigations should be used for differential 349 diagnoses of other pulmonary dysfunction causes, which—even among vulnerable populations—are 350 arguably more frequent reasons for pathological findings than previous cancer treatment, such as 351 asthma in cases of obstructive disease. Managing cases of abnormal findings and frequency of further 352 PFT depends on local institutions and guidance from local pulmonologists; it is not part of our 353 recommendations.

354 **DISCUSSION**

355 Our review summarises existing guidelines, evidence from systematic literature searches, and 356 harmonised recommendations for pulmonary dysfunction screening among CAYA cancer survivors 357 diagnosed before age 30 with exposure to potentially lung-toxic cancer treatment modalities. Because

12

358 current evidence is scarce with quality limitations and because there are no effective treatments for 359 asymptomatic pulmonary dysfunction, our panel limited recommendations for PFT to symptomatic 360 CAYA cancer survivors only. We recommend health care providers to be aware of increased risks for 361 possible pulmonary dysfunction—especially among survivors treated with allogeneic HSCT, thoracic 362 radiotherapy, and thoracic surgery; be vigilant for early clinical symptoms of pulmonary dysfunction; 363 and refer symptomatic CAYA cancer survivors to pulmonologists experienced with the population. 364 We also recommend counselling all CAYA cancer survivors about lifestyle factors relevant for 365 pulmonary and general health.

Our recommendations are supported by two additional studies specific for children following HSCT (56, 57). Both studies were not considered in our final recommendation as they formulated follow-up recommendations independent of underlying diagnosis, including HSCT for malignant diseases, immune deficiencies, inherited bone marrow failure syndromes, and haemoglobinopathies. However, after two years of follow-up, neither study recommended regular PFT for asymptomatic children and adolescents; rather they advised considering follow-up PFT based on symptoms and past measurements (56, 57).

373 Gaps in knowledge and future directions for research

With currently available evidence, we only answered a few of our original clinical questions and often to only a limited extent, such as any exposure to radiotherapy without differentiation for doses or volumes. To improve evidence on pulmonary dysfunction among CAYA cancer survivors, we outlined gaps in knowledge and methodological approaches for future research (Table 5).

We identified existing knowledge gaps for dose-response relationships of all studied exposures; newer chemotherapeutic or immunotherapeutic agents; other medical conditions, such as pulmonary complications during treatment, co-morbidities; impact of treatments on physiological processes affecting pulmonary function, such as lung growth and physiologic ageing; and also approaches for early assessment of pulmonary dysfunction and effects from preventive or curative interventions.

Most studies focused on well-established risk factors such as HSCT (31-37), thoracic radiotherapy (1-384 3, 31, 38, 40, 45-48, 50-52), and thoracic surgery (1, 31, 38-40). For chemotherapeutic agents—even those with previously reported pulmonary toxicity, such as bleomycin— we found clinical evidence

386 for CAYA cancer survivors insufficient. Future studies evaluating other classical chemotherapeutic 387 agents, targeted or immunotherapeutic agents, or pharmacovigilance data might identify new aspects 388 of pulmonary dysfunction among CAYA cancer survivors. It is similar for radiotherapy, including a 389 lack of data comparing photon and proton therapy where toxicity of protons might be lower from 390 smaller irradiated volume compared with photons, possibly resulting in less lung-toxicity. For all 391 exposures, we lack knowledge on how they interact with each other or how age at treatment or 392 additional medical conditions modify impact from exposures; we also have little information about 393 dose-response relationships.

394 Peak lung function attained in early adulthood and the trajectory of lung function decline with ageing 395 are important for lung health across the life span. The impact of cancer itself, pulmonary 396 complications during treatment, pulmonary co-morbidities, such as asthma, or impaired somatic 397 growth, such as scoliosis, on peak attained lung function has not been examined. No studies examined 398 whether CAYA cancer survivors start at a lower peak attained lung function or whether physiological 399 ageing and decline in pulmonary function is faster and steeper than among the general population. 400 Frailty and accelerated ageing were previously described for childhood cancer survivors (58-60). The 401 definition of frailty is met when fulfilling three or more of five criteria: reduced lean muscle mass, 402 weakness, slow walking speed, low energy expenditure, and fatigue (61). Ness et al. showed that 403 components of frailty-reduced strength, walking speed, and increased fatigue-were as frequent 404 among childhood cancer survivors from the St. Jude Lifetime Cohort at a median age of 33 years as 405 among people age 65 years and older in the general population (62). By calculating the deficit 406 accumulation index score, Williams et al. showed childhood cancer survivors acquire more damage 407 and disease than community controls (60). Both studies suggest accelerated ageing among childhood 408 cancer survivors. Factors contributing to accelerated ageing and frailty include more rapid cellular 409 senescence, telomere length reduction, epigenetic modifications, somatic mutations, and mitochondrial 410 DNA damage (58). These factors may also affect lung growth and function among children and 411 adolescents or result in faster pulmonary ageing, but their potential impact among CAYA cancer 412 survivors is unknown.

413 Another gap in knowledge concerns measuring early stages of pulmonary dysfunction. Prior studies 414 primarily utilized spirometry, body plethysmography, or DLCO measurement. More sensitive tests, 415 such as multiple breath washout tests, may identify pulmonary disease earlier and eventually 416 contribute to better understanding of pulmonary dysfunction development among CAYA cancer 417 survivors. Parisi et al. and Schindera et al. investigated pulmonary function of childhood cancer 418 survivors using multiple breath washout tests (63, 64). Parisi et al. investigated 57 survivors with 419 median follow-up time of 6.2 years from end of treatment; they did not show differences in ventilation 420 homogeneity compared with controls (64). The 46 survivors evaluated by Schindera et al. were 421 median 20 years from cancer diagnosis (63). Survivors defined as high risk (bleomycin, busulfan, 422 nitrosoureas, HSCT, thoracic radiotherapy, or surgery) tended to have more ventilation inhomogeneity 423 than those at standard risk (other cancer therapies), yet not significantly (63). In both studies, more 424 survivors had abnormal washout tests than abnormal spirometry.

425 Available data made it impossible to reach conclusions about the longitudinal course of pulmonary 426 function as survivors progress through childhood, puberty, and adulthood in their growth and 427 development followed by a trajectory of ageing. Eight studies with repeated PFT results suffered from 428 attrition bias, small sample sizes, and included sub-groups of CAYA cancer survivors, such as HSCT 429 (2, 32, 33, 35, 37, 47, 52, 53). Ideally with baseline PFT before starting treatment, longitudinal data— 430 ascertained at regular intervals from diagnosis—will be available improve knowledge about the onset 431 of pulmonary dysfunction and its evolution.

PFT provides one way of assessing pulmonary health. Clinical symptoms or imaging are other possible modalities. Clinical symptoms lack objectivity and vary with age, which limits precise measurement. In addition, questions about clinical symptoms are worded differently between studies, which makes comparisons difficult. Louie et al validated selected self-reported complications from HSCT survivors (65). No data exist for other CAYA cancer survivor populations or for other questions about pulmonary dysfunction.

438 We suggest future studies take weaknesses and methodological problems we identified from the 439 literature we reviewed into account and avoid them whenever possible (Table 5). Collaboration 440 between paediatric oncologists and pulmonologists helps avoid shortcomings when conducting PFT 441 and reporting results. Collaborative studies with harmonised protocols could maximise statistical 442 power with larger numbers of CAYA cancer survivors and allow stratifying analyses into sub-groups 443 defined by therapeutic exposures, age at treatment, cumulative doses, or genotype. Prospective rather 444 than retrospective studies allow for standardising assessments, such as PFT at predefined time points, 445 and minimise selection and attrition biases. Assessing patient-reported outcomes, such as symptoms, 446 functional limitations, and quality of life, together with PFT, helps determine the clinical significance 447 of findings and their impact on lives of patients and their families.

448 To obtain accurate measurements, PFT must be performed to high standards, by trained personnel 449 explicitly applying published guidelines and standards, including ERS/ATS guidelines. Reporting, 450 interpreting, and applying results in clinical practice are equally important. It is essential that future 451 studies use GLI reference equations to standardise PFT results and make them comparable between 452 age groups and regions (66, 67). Binary cut-offs—describing results as either normal or abnormal— 453 reduce statistical power and introduce interpretations based on pre-defined threshold values. Since cut-454 off values differ between studies, such dichotomisation hampers comparisons of results, leading to 455 conflicting and potentially misleading proportions of CAYA cancer survivors with pulmonary 456 dysfunction. Reporting results as raw data and z-scores based on internationally agreed, age-adjusted 457 reference values is preferred and allows comparing and pooling data.

458 We suggest studies investigating pulmonary function among CAYA cancer survivors be conducted in 459 the knowledge that at present no curative treatments exist for suspected progressive inflammatory and 460 fibrotic changes underlying pulmonary dysfunction. Therefore, we advise careful study of benefits and 461 harms from repeat testing. However, awareness of impaired pulmonary function possibly leads to 462 earlier treatment of bacterial infections with antibiotics, especially because excess pulmonary 463 mortality and hospitalisations among CAYA cancer survivors are mainly from infection (68, 69). The 464 U.S. Food and Drug Administration and European Medicines Agency approved two anti-fibrotic 465 drugs—pirfenidone and nintedanib—for the treatment of idiopathic pulmonary fibrosis; patients with 466 progressive-fibrosing unclassifiable interstitial lung disease possibly also benefit (70). Therefore, in 467 the future the possible benefit from anti-fibrotic drugs could be an area for investigation among 468 CAYA cancer survivors.

469 Strengths and limitations

470 Strengths of our recommendation are multidisciplinary and international collaboration, which included 471 perspectives from paediatric and adult specialists in CAYA cancer care and survivors; broad inclusion 472 criteria; our thorough review process paired with in-depth quality assessment of included studies; and 473 resulting evidence. Limitations mainly reflect lack of available evidence: studies with small sample 474 sizes, heterogeneous PFT result reporting, use of different reference values; and scarce longitudinal 475 data.

476 Conclusion

477 CAYA cancer survivors treated with allogeneic HSCT, thoracic radiotherapy, and thoracic surgery 478 were reported at risk for pulmonary dysfunction. However, our extensive literature search highlights 479 the absence of robust evidence linking these exposures and pulmonary dysfunction because of small 480 study sizes, high risks of bias, inconsistently assessing and reporting PFT results, and a lack of 481 effective interventions to prevent the deterioration of asymptomatic pulmonary dysfunction. 482 Therefore, our panel could not currently recommend routine PFT for asymptomatic CAYA cancer 483 survivors. Yet, it is important for health care professionals and CAYA cancer survivors to be aware of 484 possibly impaired pulmonary health and act vigilantly about appropriately investigating and following 485 up when symptoms develop. We also recommend routine vaccinations recommended for people with 486 pulmonary diseases and careful counselling relating to avoidance of tobacco products. Our results 487 highlighted the current paucity of evidence, revealed relevant knowledge gaps, and emphasised that 488 clearly defined, well-planned, harmonised, and collaborative studies and reports of pulmonary 489 function outcomes are urgently needed to improve the body of evidence about pulmonary function 490 among CAYA cancer survivors in the future.

491 Acknowledgment

We thank Elio Castagnola and Cecile Ronckers for their contribution to the title and abstract and full
text screening; Prof Thorsten Langer (Pediatric Oncology and Hematology, University Hospital for
Children and Adolescents, Lübeck, Germany) and Daniel Mulrooney (St Jude Children's Research
Hospital, Memphis, TN, USA) for critically appraising the recommendations and manuscript as
external reviewers; and Anna Apel (CEO of Saving Kids with Cancer Foundation, Poland; PanCare

497 Board Member) and Katie Weyer as survivor representatives. Lastly, we thank Kristin Marie Bivens

- 498 (Institute of Social and Preventive Medicine, University of Bern) for her editorial assistance.
- 499

500 Author contributions

- 501 Concept and design: CEK, ACD, RLM, SHA, MMH, LK, RK
- 502 Literature search: CEK, RLM, RK, MO
- 503 Title and abstract screening: all authors
- 504 Full text screening: all authors
- 505 Data extraction: all authors
- 506 Risk of bias assessment: CEK, RLM, RK, MO, CS, MG, NW
- 507 Quality of evidence assessment: CEK, RLM, RK, MO, CS, MG, NW
- 508 Manuscript writing: all authors
- 509 Manuscript review: all authors
- 510

511 MO and RK have directly accessed and verified all underlying data reported in the manuscript.

512 All authors had full access to all the data in the study and accept responsibility for the submission for 513 publication.

- 514
- 515

516 **Declaration of interest** 517 - AC Dietz is emplo

AC Dietz is employed by and has equity in Shape Therapeutics, Inc. and was employed by 518 and has equity in bluebird bio, Inc., neither of which provided financial support or 519 oversight of this work. 520 _ AB received fees for lectures and/or boards from Astra-Zeneca, Novartis, Enanta paid to 521 her institution as well as travel grants from Boehringer and Astra-Zeneca. 522 CEK received grants from the Swiss National Science Foundation _ 523 DJW received grants/contracts from Vertex pharmaceuticals, Cystic Fibrosis Foundation, _ 524 Cystic Fibrosis Foundation Therapeutic Development Network, payment or honoraria for 525 lectures/ presentations by Cystic Fibrosis Foundation and American Board of Pediatrics 526 GS and RK received support for the present manuscript by Bernische Krebsliga and -527 Lungenliga Bern 528 LSC received support from University of Alabama for COG Survivorship guidelines, 529 royalties or licenses from Springer and Wolters Kluwer, payment or honoraria for 530 lectures/ presentations from the American Society for Hematology and the University of 531 Miami, travel support from the First International Pediatric Cardio-oncology meeting, and 532 participates on the Data Safety Monitoring Board or Advisory Board of the NCI PDQ 533 MG received a grant from the Swiss National Science Foundation, support for attending 534 meetings and/or travel from the European Respiratory Society, has a leadership role in the 535 **BEAT-PCD ERS clinical research collaboration** 536 NW received general research support from CANSEARCH Research Foundation, 537 payment/honoraria and support to attend an international meeting from Swedish Orphan 538 Biovitrum (SOBI), participates on a Data Safety Monitoring Board or Advisory Board 539 from SOBI 540 PL received grants/contracts from Vertex and OM Pharma, payments or honoraria for 541 lectures/ presentations by Vertex, Vifor and OM Pharma, participates on a Data Safety 542 Monitoring Board or Advisory Board from Polyphor, Santhera, Vertex, OM Pharma, 543 Vifor, Sanofi Aventis

- 544
- UH received a grant and support for attending meetings from the German Childhood Cancer Foundation.
- 545 546
- 547

548 Funding

549 Swiss Cancer Research (grant no: KFS-4157-02-2017, KLS/KFS-4825-01-2019 and KFS-5302-02-550 2021), Cancer League Bern, Kinderkrebshilfe Schweiz, and Lung League Bern provided support for 551 our study. Funders played no role in study design, data collection and analysis, decision to publish, or 552 preparation of the manuscript.

- 553
- 554 555

556 References

- Mulder RL, Thonissen NM, van der Pal HJ, Bresser P, Hanselaar W, Koning CC, et al.
 Pulmonary function impairment measured by pulmonary function tests in long-term survivors of childhood cancer. Thorax. 2011;66(12):1065-71.
- Armenian SH, Landier W, Francisco L, Herrera C, Mills G, Siyahian A, et al. Long-term pulmonary function in survivors of childhood cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015;33(14):1592-600.
- Green DM, Zhu L, Wang M, Ness KK, Krasin MJ, Bhakta NH, et al. Pulmonary function after
 treatment for childhood cancer. A report from the St. Jude Lifetime Cohort Study (SJLIFE).
 Annals of the American Thoracic Society. 2016;13(9):1575-85.
- Reulen RC, Winter DL, Frobisher C, Lancashire ER, Stiller CA, Jenney ME, et al. Long-term cause-specific mortality among survivors of childhood cancer. Jama. 2010;304(2):172-9.
- 5. Schindler M, Spycher BD, Ammann RA, Ansari M, Michel G, Kuehni CE, et al. Cause-specific
 long-term mortality in survivors of childhood cancer in Switzerland: A population-based study.
 International journal of cancer. 2016;139(2):322-33.
- 571
 6. Huang TT, Hudson MM, Stokes DC, Krasin MJ, Spunt SL, Ness KK. Pulmonary outcomes in survivors of childhood cancer: a systematic review. Chest. 2011;140(4):881-901.
- 573
 7. Skinner R, Kaplan R, Nathan PC. Renal and pulmonary late effects of cancer therapy. Seminars in oncology. 2013;40(6):757-73.
- 8. Hildebrandt GC, Fazekas T, Lawitschka A, Bertz H, Greinix H, Halter J, et al. Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. Bone marrow transplantation. 2011;46:1283.
- 578
 9. Saglio F, Zecca M, Pagliara D, Giorgiani G, Balduzzi A, Calore E, et al. Occurrence of longterm effects after hematopoietic stem cell transplantation in children affected by acute leukemia receiving either busulfan or total body irradiation: results of an AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) retrospective study. Bone marrow transplantation. 2020;55(10):1918-27.
- 583
 10. Straub JM, New J, Hamilton CD, Lominska C, Shnayder Y, Thomas SM. Radiation-induced
 fibrosis: mechanisms and implications for therapy. J Cancer Res Clin Oncol.
 2015;141(11):1985-94.
- 11. Robinson PD, Latzin P, Verbanck S, Hall GL, Horsley A, Gappa M, et al. Consensus statement for inert gas washout measurement using multiple- and single- breath tests. The European respiratory journal. 2013;41(3):507-22.
- 589 12. Stenehjem JS, Smeland KB, Murbraech K, Holte H, Kvaløy S, Wethal T, et al. Diffusing
 590 capacity impairment is prevalent in long-term lymphoma survivors after high-dose therapy with
 591 autologous stem cell transplantation. Bone marrow transplantation. 2016;52:646.
- 592 13. Botta L, Gatta G, Capocaccia R, Stiller C, Cañete A, Dal Maso L, et al. Long-term survival and
 593 cure fraction estimates for childhood cancer in Europe (EUROCARE-6): results from a
 594 population-based study. The Lancet Oncology. 2022;23(12):1525-36.
- 595 14. Children's Oncology Group Long Term Follow-Up guidelines Version 5.0 2018 [cited 2019
 596 05.04.2019]. Available from:
- 597 http://www.survivorshipguidelines.org/pdf/2018/COG_LTFU_Guidelines_v5.pdf.

598	15.	Dutch Children's Oncology Group SKION. Guidelines for follow-up in survivors of childhood
599		cancer 5 years after diagnosis. 2010 [cited 08.05.2018]. Available from:
600		https://www.skion.nl/voor-patienten-en-ouders/late-effecten/533/richtlijn-follow-up-na-
601		kinderkanker/.
602	16.	United Kindgdom Chilren's Cancer Study Group. Therapy based long term follow-up - Practice
603		Statement 2005. [cited 08.05.2018]. Available from:
604		https://www.cclg.org.uk/write/MediaUploads/Member%20area/Treatment%20guidelines/LTFU
605		-full.pdf.
606	17.	International Guideline Harmonization Group (IGHG). [cited 04.11.2020]. Available from:
607		https://www.ighg.org/.
608	18.	Kremer LC, Mulder RL, Oeffinger KC, Bhatia S, Landier W, Levitt G, et al. A worldwide
609		collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult
610		cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline
611		Harmonization Group. Pediatric blood & cancer. 2013:60(4):543-9.
612	19.	Children's Oncology Group Long Term Follow-Up guidelines Version 4.0 2013 [cited
613		0.05.2018]. Available from: https://www.childrensoncologygroup.org/.
614	20.	Children's Cancer and Leukaemia Group. [cited 29.05.2022]. Available from:
615	_0.	https://www.cclg.org.uk/
616	21	PanCare - Pan-European Network for Care of Survivors after Childhood and Adolescent
617	21.	Cancer [cited 29.05.2022] Available from: www.pancare.eu
618	22	Scottish Intercollegiate Guidelines Network (SIGN) Long term follow up of survivors of
619	22.	childhood cancer - A national clinical guideline 2013 [cited 16 11 2021] Available from:
620		https://www.sign.ac.uk/media/1070/sign132.pdf
620 621	23	Centre for Evidence-Based Medicine (CEBM) Asking focused questions: University of Oxford
622	25.	Oxford LIK [cited 20.05 2022] Available from: https://www.cahm.ov.ac.uk/resources/ahm-
623		tools/asking focused-questions
624	24	Otth M. Schinders C. Güngör T. Ansari M. Scheinemann K. Belle FN. et al. Transplant
625	24.	abaractoristics and salf reported pulmonary outcomes in Swiss shildhood sensor survivors after
626		baretopointie stam call transplantation a schort study. Pone marrow transplantation 2021:
627		56(5):1065 1076
628	25	So(S).1005-1070. Kastalar P. Waiss A. Schindlar M. Sommar G. Latzin P. von der Weid NY, at al. Long term
620	25.	nulmonary disease among Swiss shildhood senser survivors. Dedistric blood & senser
630		2018:65(1)
631	26	Diotz AC Chan V Vacui V Naca KK Hagood IS Chaw EL at al Disk and impact of
632	20.	Dietz AC, Chell I, Tasul I, Ness KK, Hagoou JS, Chow EJ, et al. Kisk and impact of
622		Survivor Study, Cancer 2016;122(22):2697.06
624	27	Survivoi Study. Caller. 2010,122(25).5067-90. Martana A.C. Vasui V. Liu V. Stavall M. Hutahingan D. Cinghang L at al. Dulmonary.
625	27.	applications in survivors of shildhood and adalassant sensor. A report from the Childhood
626		Complexitions in survivors of childhood and addresscent cancer. A report from the Childhood
030 627	20	Lucan Cancer Survivor Study. Cancer. 2002;95(11):2451-41.
629	28.	Huang 11, Chen Y, Dielz AC, Yasur Y, Donaidson SS, Stokes DC, et al. Pulmonary outcomes
030 620		In survivors of childhood central hervous system mangnancies: a report from the Childhood
039	20	Cancer Survivor Study. Pediatric blood & cancer. $2014;61(2):319-25$.
640	29.	Moner D, Liberati A, Tetziari J, Altman DG. Preferred reporting items for systematic reviews
041	20	and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):330-41.
042	30.	Atkins D, Best D, Briss PA, Eccles M, Faick-Ytter Y, Flottorp S, et al. Grading quality of
643	21	evidence and strength of recommendations. BMJ. 2004;328(7454):1490.
644	31.	Record E, Williamson R, Wasilewski-Masker K, Mertens AC, Meacham LR, Popler J. Analysis
645		of risk factors for abnormal pulmonary function in pediatric cancer survivors. Pediatric blood &
646	~ ~	cancer. 2016;63(7):1264-71.
647	32.	Inaba H, Yang J, Pan J, Stokes DC, Krasın MJ, Srinivasan A, et al. Pulmonary dysfunction in
048		survivors of childhood hematologic malignancies after allogeneic hematopoietic stem cell
649	~~	transplantation. Cancer. 2010;116(8):2020-30.
650	33.	Ginsberg JP, Aplenc R, McDonough J, Bethel J, Doyle J, Weiner DJ. Pre-transplant lung
651		tunction is predictive of survival following pediatric bone marrow transplantation. Pediatric
652		blood & cancer. 2010;54(3):454-60.

653	34.	Leung W, Ahn H, Rose SR, Phipps S, Smith T, Gan K, et al. A prospective cohort study of late
654		sequelae of pediatric allogeneic hematopoietic stem cell transplantation. Medicine.
655		2007;86(4):215-24.
656	35.	Madanat-Harjuoja LM, Valjento S, Vettenranta K, Kajosaari M, Dyba T, Taskinen M.
657		Pulmonary function following allogeneic stem cell transplantation in childhood: a retrospective
658		cohort study of 51 patients. Pediatric transplantation. 2014;18(6):617-24.
659	36.	Hoffmeister PA, Madtes DK, Storer BE, Sanders JE. Pulmonary function in long-term survivors
660		of pediatric hematopoietic cell transplantation. Pediatric blood & cancer. 2006;47(5):594-606.
661	37.	Wieringa J, van Kralingen KW, Sont JK, Bresters D. Pulmonary function impairment in
662		children following hematopoietic stem cell transplantation. Pediatric blood & cancer.
663		2005;45(3):318-23.
664	38.	De A, Kamath S, Wong K, Olch AJ, Malvar J, Sposto R, et al. Correlation of pulmonary
665		function abnormalities with dose volume histograms in children treated with lung irradiation.
666		Pediatric pulmonology. 2015;50(6):596-603.
667	39.	Denbo JW, Zhu L, Srivastava D, Stokes DC, Srinivasan S, Hudson MM, et al. Long-term
668		pulmonary function after metastasectomy for childhood osteosarcoma: a report from the St Jude
669		lifetime cohort study. Journal of the American College of Surgeons. 2014;219(2):265-71.
670	40.	Stone A, Friedman DN, Kushner BH, Wolden S, Modak S, LaQuaglia MP, et al. Assessment of
671		pulmonary outcomes, exercise capacity, and longitudinal changes in lung function in pediatric
672		survivors of high-risk neuroblastoma. Pediatric blood & cancer. 2019;66(11):e27960.
673	41.	Nysom K, Holm K, Hertz H, Hesse B. Risk factors for reduced pulmonary function after
674		malignant lymphoma in childhood. Medical and pediatric oncology. 1998;30(4):240-8.
675	42.	Nysom K, Holm K, Olsen JH, Hertz H, Hesse B. Pulmonary function after treatment for acute
676		lymphoblastic leukaemia in childhood. British journal of cancer. 1998;78(1):21-7.
677	43.	Oancea SC, Gurney JG, Ness KK, Oiha RP, Tvc VL, Klosky JL, et al. Cigarette smoking and
678		pulmonary function in adult survivors of childhood cancer exposed to pulmonary-toxic therapy:
679		results from the St. Jude lifetime cohort study. Cancer epidemiology, biomarkers & prevention.
680		2014:23(9):1938-43.
681	44.	Myrdal OH, Kanellopoulos A, Christensen JR, Ruud E, Edvardsen E, Kongerud J, et al. Risk
682		factors for impaired pulmonary function and cardiorespiratory fitness in very long-term adult
683		survivors of childhood acute lymphoblastic leukemia after treatment with chemotherapy only.
684		Acta oncologica (Stockholm, Sweden), 2018:57(5):658-64.
685	45.	Zorzi AP. Yang CL, Dell S, Nathan PC, Bleomycin-associated Lung Toxicity in Childhood
686		Cancer Survivors. Journal of pediatric hematology/oncology, 2015:37(8):e447-52.
687	46.	Jenney ME, Faragher EB, Jones PH, Woodcock A, Lung function and exercise capacity in
688		survivors of childhood leukaemia. Medical and pediatric oncology, 1995:24(4):222-30.
689	47.	Green DM. Merchant TE. Billups CA. Stokes DC. Broniscer A. Bartels U. et al. Pulmonary
690		function after treatment for embryonal brain tumors on SIMB03 that included craniospinal
691		irradiation. International journal of radiation oncology, biology, physics, 2015;93(1):47-53.
692	48.	Khan F. Williams AM. Weiner DJ. Constine LS. Impact of Respiratory Developmental Stage on
693		Sensitivity to Late Effects of Radiation in Pediatric Cancer Survivors Adv Radiat Oncol
694		2020.5(3).426-33
695	49	Mittal A Bhethanabhotla S Ganguly S Vishnubhatla S Khadgawat R Patel C et al. Late
696	17.	effects in pediatric Hodgkin lymphoma survivors after uniform treatment with ABVD with or
697		without radiotherany. Pediatric blood & cancer 2021:68(11):e29293
698	50	Weiner DI Maity A Carlson CA Ginsberg IP Pulmonary function abnormalities in children
699	50.	treated with whole lung irradiation. Pediatric blood & cancer 2006:46(2):222-7
700	51	Oguz A Tayfun T Citak EC Karadeniz C Tatlicioglu T Boyunaga O et al Long-term
700	51.	nulmonary function in survivors of childhood Hodgkin disease and non-Hodgkin lymphoma
701		Pediatric blood & cancer 2007:40(5):600.703
702	52	Otth M. Vammine S. Usemann I. Latzin P. Mader I. Snycher B. et al. Longitudinal lung
704	54.	function in childhood cancer survivors after hematonoietic stem call transplantation. Bone
705		marrow transplantation 2022.57(2).207-14
706	53	Marina NM Greenwald CA Fairclough DI Thompson EI Wilimas IA Mackart DW at al
707	55.	Serial nulmonary function studies in children treated for newly diagnosed Hodgkin's diagnose
709		with months redictherapy plus evoles of evolution been been dening the second proceeder of evolution been been been been been been been be
100		with manue radiotherapy plus cycles of cyclophosphannue, vinchstnie, and procardazine

709		alternating with cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine. Cancer.		
710		1995;75(7):1706-11.		
711	54.	Donat SM, Levy DA. Bleomycin associated pulmonary toxicity: is perioperative oxygen		
712		restriction necessary? The Journal of urology. 1998;160(4):1347-52.		
713	55.	LaMantia KR, Glick JH, Marshall BE. Supplemental oxygen does not cause respiratory fai		
714		in bleomycin-treated surgical patients. Anesthesiology. 1984;60(1):65-7.		
715	56.	Chow EJ, Anderson L, Baker KS, Bhatia S, Guilcher GMT, Huang JT, et al. Late Effects		
716		Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell		
717		Transplantation: A Children's Oncology Group Report. Biology of Blood and Marrow		
718		Transplantation. 2016:22(5):782-95.		
719	57.	Dietz AC, Duncan CN, Alter BP, Bresters D, Cowan MJ, Notarangelo L, et al. The Second		
720	071	Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on		
721		Late Effects after Pediatric Hematopoietic Cell Transplantation: Defining the Unique Late		
722		Effects of Children Undergoing Hematopoietic Cell Transplantation for Immune Deficiencies		
723		Inherited Marrow Failure Disorders, and Hemoglobinonathies, Biology of Blood and Marrow		
723		Transplantation 2017:23(1):24.0		
724	58	Nass KK Kirkland II. Gramataas MM Wang 7 Kundu M McCastlain K at al Dramatura		
725	56.	Developsion A ging as a Deredigm for Linderstanding Increased Dick of Adverse Health Across		
720		the Lifespon of Sumiyors of Childhood Conson, Journal of alinical angelogy, 2018;26(21):2206		
727		the Effestion of Survivors of Childhood Calcel. Journal of Childran Oncology. 2018,50(21).2200-		
720	50	13. Armanian SIL Cibson CL Bookna DC Ness VK Dramatura Aging in Young Cancer Survivora		
729	39.	Armelian SH, Gloson CJ, Rockner KC, Ness KK. Flemature Aging in Foung Cancel Survivors.		
730	60	Journal of the National Cancer Institute. 2019;111(5):220-52.		
731	60.	Williams Alvi, Mandelblau J, wang M, Armstrong GT, Bhakta N, Brinkman TM, et al.		
132		Premature aging as an accumulation of deficits in young adult survivors of pediatric cancer.		
133	C 1	Journal of the National Cancer Institute. $2023;115(2):200-7$.		
/34	61.	Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older		
135		adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146-56.		
736	62.	Ness KK, Krull KR, Jones KE, Mulrooney DA, Armstrong GT, Green DM, et al. Physiologic		
737		frailty as a sign of accelerated aging among adult survivors of childhood cancer: a report from		
738		the St Jude Lifetime cohort study. Journal of clinical oncology. 2013;31(36):4496-503.		
739	63.	Schindera C, Usemann J, Zuercher SJ, Jung R, Kasteler R, Frauchiger B, et al. Pulmonary		
740		Dysfunction after Treatment for Childhood Cancer. Comparing Multiple-Breath Washout with		
741		Spirometry. Annals of the American Thoracic Society. 2021;18(2):281-9.		
742	64.	Parisi GF, Cannata E, Manti S, Papale M, Meli M, Russo G, et al. Lung clearance index: A new		
743		measure of late lung complications of cancer therapy in children. Pediatric pulmonology.		
744		2020;55(12):3450-6.		
745	65.	Louie AD, Robison LL, Bogue M, Hyde S, Forman SJ, Bhatia S. Validation of self-reported		
746		complications by bone marrow transplantation survivors. Bone marrow transplantation.		
747		2000;25(11):1191-6.		
748	66.	Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference		
749		values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. The		
750		European respiratory journal. 2012;40(6):1324-43.		
751	67.	Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al.		
752		Standardization of Spirometry 2019 Update. An Official American Thoracic Society and		
753		European Respiratory Society Technical Statement. American journal of respiratory and critical		
754		care medicine. 2019;200(8):e70-e88.		
755	68.	Fidler MM, Reulen RC, Bright CJ, Henson KE, Kelly JS, Jenney M, et al. Respiratory mortality		
756		of childhood, adolescent and young adult cancer survivors. Thorax. 2018;73(10):959-68.		
757	69.	Smith L, Glaser AW, Peckham D, Greenwood DC, Feltbower RG. Respiratory morbidity in		
758		young people surviving cancer: Population-based study of hospital admissions, treatment-		
759		related risk factors and subsequent mortality. International journal of cancer. 2018:145(1):20-8.		
760	70.	Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ. Molina-Molina M. et al. Pirfenidone in		
761		patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind		
762		randomised, placebo-controlled, phase 2 trial. The Lancet Respiratory medicine. 2020:8(2):147-		
763		57.		
764				



PRISMA 2009 Flow Diagram



From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting /tems for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit <u>www.prisma-statement.org</u>.

Figure 1: Flow diagram for selection of studies

(Studies could be included in more than one category)

Table 1: Key characteristics of included studies used for recommendation (n=26). Detailed information available in Appendix K.	
--	--

Author	 Population 1. Number of survivors analysed (treatment years) 2. Diagnostic group 3. Proportion of survivors exposed to specific treatments 	Outcome relevant for recommendation 1. Pulmonary function parameters assessed 2. Definition of pulmonary dysfunction
Armenian et al., J Clin Oncol 2015^2	1. N=121 (1972–2007) 2. Treatment related inclusion criteria: no restriction for	1. TLC, FVC, FEV1, FEV1/FVC, DLCO 2. Obstructive=EEV1/EVC<0.7 EEV1<80% pred
01101, 2015	 2. Treatment-related inclusion criteria, no restriction for cancer diagnosis, at least one pulmonary toxic treatment modality (1) pulmonary toxic chemotherapy (bleomycin, busulfan, nitrosoureas), and/or 2) chest radiation, and/or 3) allogeneic HSCT with cGVHD, and/or 4) pulmonary surgery (lobectomy, metastasectomy, or wedge resection) 3. Exposure/PICO: Bleomycin 35%, busulfan 12%, nitrosoureas 10%, radiotherapy 74%, surgery 6%, HSCT 36% 	Restrictive=TLC<75%pred, FEV1≥80%pred Diffusion capacity impairment =DLCO<75%pred
De et al., Pediatr	1. N=49 (1999–2009)	1. FEV1, FVC, FEV1/FVC, FEF25-75, RV, TLC. RV/TLC, phase II
Pulmonol, 2015 ³⁸	2. Treatment-related inclusion criteria: no restriction for	N ₂ , DLCO
	 cancer diagnosis, radiotherapy involving the lung 3. Exposure/PICO: Bleomycin 78%, cyclophosphamide 82%, radiotherapy 100%, surgery 18% 	 2. Obstructive=FEV1/FVC <80% pred or abnormal FEV1 or FEF25-75% pred with normal lung volumes (i.e., normal TLC) Restrictive=TLC <77% pred Hyperinflation= RV/TLC ratio >28% Diffusion capacity impairment= DLCOadj <65% pred or DLCOadj/VA <4 ml/mm/Hg/min/L
Denbo et al., J Am Coll	1. N=21 (1968–1998)	1. FVC, FEV1, TLC, DLCO
Surg, 2014 ³⁹	 Treatment-related inclusion criteria: diagnosis of osteosarcoma and pulmonary metastasectomy Exposure/PICO: Bleomycin 28%, surgery 100% 	2. Threshold for pathological parameters=FVC <80% pred; FEV1 <80% pred; TLC <75% pred; DLCOcorr <75% pred Obstructive=FEV1/FVC < 0.70 Restrictive=TLC <75% pred
Ginsberg et al., PBC,	1. N=317 (1978–2005)	1. FEV1, FVC, TLC, FEF25–75, FVC, TLC, DLCO
2010 ³³	2. Treatment-related inclusion criterion: first myeloablative SCT (autologous or allogeneic) and at least one PFT available	2. Threshold for pathological parameters=FEV1, FEF25–75%, FVC, TLC, DLCO as z-scores if below -2 z-scores
	3 Exposure/PICO: Allogeneic SCT 76% TBI 55%	

Croop at al. Int I Dadiat	1 N - 260 (2002 2010)	1 EEV1 EVC TLC DLCO		
Oncol Riol Phys. 2015 ⁴⁷	 N=200 (2005-2010) Treatment related inclusion criterion: ambryonal brain 	2. Threshold for nathological narameters-EEV1<80% prod. EVC		
Oncor Dioi 1 1198, 2015	2. Treatment-related metasion effection, emoryonal oran	<80% pred DI CO<75% pred TI C<75% pred		
	3 Exposure/PICO: Cyclophosphamide 100%	(00%pred, DLeo (75%pred, TLe (75% pred		
	craniospinal radiotherapy 100%			
Green et al Ann Am	1 N=606 (unknown SILIFE)	1 FEV1 EVC TLC DLCO		
Thorac Soc. 2016^3	2. Treatment-related inclusion criteria: no restriction for	2. Threshold for pathological parameters=FEV1<80%pred.		
1110140 200, 2010	cancer diagnosis, at least one pulmonary toxic	FVC<80%pred, FEV1/FVC<0.7. TLC<75%pred.		
	treatment modality (1) bleomycin, busulfan, BCNU, or	DLCOcorr<75%pred		
	CCNU; and/or (2) radiation therapy to the chest, whole lung,			
	mediastinum, axilla, mini-mantle, mantle, extended mantle, total			
	lymphoid irradiation, subtotal lymphoid irradiation, or total body			
	metastasectomy or wedge resection) at least one PFT			
	measurement			
	3. Exposure/PICO: Bleomycin 21.3%, busulfan 2.6%.			
	cvclophosphamide 64.5%, nitrosoureas 3.8%.			
	radiotherapy 76.7%, surgery 19.7%, HSCT 6.6%			
Hoffmeister et al., PBC,	1. N=215 (1969–1995)	1. FEV1, FVC, FEV1/FVC, TLC, DLCO		
2006^{36}	2. Treatment-related inclusion criterion: myeloablative HSCT	2. Threshold for pathological parameters=TLC<80%, FVC, FEV1, FEV1/FVC<80%, DLCO<70%		
	3. Exposure/PICO: Cyclophosphamide proportion not reported, TBI 88%			
Inaba et al., Cancer,	1. N=89 (1990–2005)	1. FEV1, FVC, TLC, DLCO, FEF25-75, RV, FRC		
2010^{32}	2. Treatment-related inclusion criteria: allogeneic HSCT	2. Threshold for pathological parameters=FEV1, FVC, TLC,		
	and available PFT before HSCT	DLCOcorr <80% pred, FEF25-75 <67% pred, RV and FRC		
	3. Exposure/PICO: Cyclophosphamide 95%,	>120%pred. FEV1/FVC<0.8. RV/TLC>0.3.		
	radiotherapy (TBI) 97%	Obstructive=FEV1/FVC<0.8, FEV1<80%pred, FEF25–75 <67%pred		
		Restrictive=FVC<80% pred, TLC<80% pred,		
Jenney et al., Med	1. N=69 (1954–1988)	1. EV1, FVC, RV, FRC, ITGV, RAW, SGAW, TLC, DLCO		
Pediatr Oncol, 1995 ⁴⁶	2. Treatment-related inclusion criterion: acute	2. Threshold for pathological parameters=FEV1, FVC, RV, FRC,		
	leukaemia, at least one PFT available	ITGV, RAW, SGAW, TLC, DLCO analyzed as <80% pred and		
	3. Exposure/PICO: Cyclophosphamide (proportion not	<85% pred		
	reported), craniospinal irradiation 14%			

Khan et al., Adv Radiat	1. N=61 (1995–2016)	1. FEV1, FVC, FVC, TLC, DLCO	
Oncol, 2020 ⁴⁸	2. Treatment-related inclusion criteria: no restriction for	2. Obstructive=FVC z-score >-1.645, FEV1 z-score <-1.645, FEV1/FVC ratio z-score <-1.645. Restrictive=TLC z-score	
	cancer diagnosis, radiotherapy to the lung		
	3. Exposure/PICO: Bleomycin 59%, radiotherapy 100%	<-1.645. Hyperinflation=RV/TLC ratio z-score >+1.645. DLCO	
		z-score <-1.645	
Leung et al., Medicines	1. N=155 (1990–2003)	1. FEV1, FVC, FEV1/FVC, TLC, DLCO	
(Baltimore), 2007 ³⁴	2. Treatment-related inclusion criteria: no restriction for	2. Threshold for pathological parameters=FEV1/FVC<85%pred,	
	cancer diagnosis, allogeneic HSCT	TLC and DLCO <80% pred	
	3. Exposure/PICO: Allogeneic HSCT 100%, TBI 79%		
Madanat-Harjuoja et al.,	1. N=51 (1993–2005)	1. FEV1, FVC, FEV1/FVC	
Pediatr Transplant,	2. Treatment-related inclusion criteria: no restriction for	2. Obstructive=FEV1<80% and FEV1/FVC<80%	
2014 ³⁵	cancer diagnosis, allogeneic HSCT	Restrictive=FVC<80% and FEV1/FVC>80%	
	3. Exposure/PICO: Cyclophosphamide 47%, TBI 98%,		
	total nodal irradiation 2%		
Marina et al., Cancer,	1. N=37 (1983–1988)	1. VC, TLC, DLCO	
1995 ⁵³	2. Treatment-related inclusion criteria: Hodgkin	2. Threshold for pathological parameters=FVC, TLC, DLCO,	
	lymphoma plus mantle radiotherapy plus	DLCO/VA as % predicted; no cut-off values defined	
	chemotherapy with COP and ABVD		
	3. Exposure/PICO: Bleomycin 100%, mantle		
	radiotherapy 100%		
Mittal et al., PBC,	1. N=154 (2003–2013)	1. FEV1, FVC, DLCO	
202149	2. Treatment-related inclusion criteria: Hodgkin	2. Threshold for pathological parameters=FEV1, FVC, DLCO	
	lymphoma	<80% pred	
	3. Exposure/PICO: Bleomycin 100%	Restrictive=FVC<80% pred, FEV1/FVC≥85	
		Mixed=FVC<80%pred, FEV1/FVC<85	
Mulder et al., Thorax,	1. N=193 (1966–1996)	1. TLC, FVC, FEV1, FEV1/VC, DLCO	
2011	2. Treatment-related inclusion criteria: no restriction for	2. Obstructive=FEV1/VC _{max} <0.70 and FEV1 $<80\%$ pred	
	cancer diagnosis, at least one pulmonary toxic	Restrictive=TLC <75% pred or FVC <75% pred with normal	
	treatment modality (bleomycin, pulmonary radiotherapy	$FEV1/VC_{max}$ ratio if no TLC available	
	and/or pulmonary surgery)	Diffusion capacity impairment=DLCO or KCO <75% pred	
	5. Exposure/PICO: Bleomycin 5/%, radiotherapy		
	40.9%, surgery 16.6%		

Myrdal et al., Acta Oncol, 2018 ⁴⁴	 N=116 (1970-2002) Treatment-related inclusion criteria: acute lymphoblastic leukaemia (chemotherapy only) 	 FEV1, FVC, FEV1/FVC, TLC, RV, DLCO Threshold for pathological parameters=FVC, FEV1, FE1/FVC, TLC, RV, DLCO, DLCO/VA; reported as absolute values and
	3. Exposure/PICO: Smoking 19%	percentage of predicted
		Obstructive= FEV I/FVC <0.7
Nycom et al Dr I	$1 N_{-04} (1070 1000)$	$\frac{1}{1} = \frac{1}{1} = \frac{1}$
Concer 1008^{42}	1. N=94 (1970–1990) 2. Treatment related inclusion criteria: Acuta	1. FEV1, FVC, FLC, DLCO 2. Threshold for pathological parameters-FEV1, EVC, TLC, DLCO
Calleer, 1998	lymphoblastic leukaemia	as z-scores, abnormal if >1.645 residual SD from predicted mean
	3 Exposure/PICO: Cyclophosphamide 46%	values
	methotrexate 73%, smoking (former or current) 23%	Obstructive=low FEV1/FVC
		Restrictive=reduced FVC or TLC or restrictive flow-volume curve
Nysom et al., Med	1. N=41 (1970–1992)	1. FEV1, FVC, TLC, DLCO
Padiatr Oncol, 1998 ⁴¹	2. Treatment-related inclusion criteria: Hodgkin and	2. Threshold for pathological parameters=FEV1, FVC, TLC, DLCO
	non-Hodgkin lymphoma	as z-scores, abnormal if >1.645 residual SD from predicted mean
	3. Exposure/PICO: Radiotherapy 51%	values
Oancea et al., Cancer	1. N=433 (unknown)	1. FEV1, FVC, TLC, DLCO
Epidemiol Biomarkers	2. Treatment-related inclusion criteria: no restriction for	2. Obstructive=FEV1/FVC <0.70
Prev, 2014 ⁴³	cancer diagnosis, at least one pulmonary toxic	Restrictive=TLC<75%pred
	treatment modality (pulmonary lobectomy, metastasectomy or	
	radiotherapy to the chest, whole lung, mediastinum, axilla, mini-	
	mantle, mantle, extended mantle, total lymphoid irradiation,	
	subtotal lymphoid irradiation, or total body irradiation)	
	3. Exposure/PICO: Bleomycin 22%, busulfan 2%,	
Oguz et al. PBC 2007 ⁵¹	1 N -75 (1992) 2003)	1 FEV1 EVC FEV1/EVC TLC BV BV/TLC DLCO
Oguz et al., 1 DC, 2007	2 Treatment-related inclusion criteria: Hodokin and	2 Obstructive by FEV1 FVC FEV1/FVC Restrictive by TLC RV
	non-Hodgkin lymphoma	RV/TLC ratio. Diffusion capacity impairment by DLCO. No
	3. Exposure/PICO: Radiotherapy 55%	further information.
Otth et al., Bone	1. N=74 (1976–2010)	1. FEV1, FVC, MMEF, TLC, RV, DLCO
Marrow Transplant,	2. Treatment-related inclusion criteria: autologous or	2. Threshold for pathological parameters=FEV1, FVC, MMEF, TLC,
2022^{52}	allogeneic HSCT	RV, DLCO as z-scores, abnormal if z-scores <-1.645
	3. Exposure/PICO: Radiotherapy 70%, thoracic surgery	
	14%, allogeneic HSCT, 68%, busulfan 34%,	
	carmustine 7%, lomustine 1%, bleomycin 5%	

Record et al., PBC,	1. N=143 (2000–2009)	1. FEV1, FVC, FEV1/FVC, FEF25-75, TLC, RV		
2016^{31}	2. Treatment-related inclusion criteria: no restriction for	2. Obstructive= FVC <80% pred.; FEV1<80% pred or FEV1/FVC<80% pred, or FEF25-75% <68% pred		
	cancer diagnosis, at least one pulmonary toxic			
	treatment modality (bleomycin, busulfan, carmustine,	Restrictive=TLC <80% pred		
	lomustine; radiation to the chest (mantle, mediastinal, whole lung	Hyperinflation=RV>120%pred or RV/TLC >28%pred		
	or surgery to the chest or lung (lobectomy, wedge resection, or			
	thoracotomy))			
	3. Exposure/PICO: Bleomycin 33.6%, nitrosoureas			
	11.9%, radiotherapy 67.8%, surgery 16.8%, HSCT			
	46.9%			
Stone et al., PBC,	1. N=62 (1996–2013)	1. FEV1, FVC, FEF25-75, TLC, DLCO		
2020^{40}	 Treatment-related inclusion criteria: High-risk neuroblastoma 	2. Threshold for pathological parameters=FEV1, FVC, TLC, DLCO <80% pred		
	3. Exposure/PICO: Busulfan 6.5%, cyclophosphamide	Obstructive=FEV1/FVC<0.8		
	100%, radiotherapy 34%, surgery 23%	Restrictive=TLC<80 % pred		
Weiner et al., PBC,	1. N=30 (1988–2003)	1. FVC, FEV1, FEV1/FVC, TLC, DLCO, MIP, MEP		
2006^{50}	2. Treatment-related inclusion criteria: no restriction to	2. Each pulmonary function parameter was considered normal if it		
	cancer diagnosis, whole lung irradiation	was within two standard deviations of the mean $(-2 < Z < 2)$		
	3. Exposure/PICO: Bleomycin 10%, radiotherapy 100%			
Wieringa et al., PBC,	1. N=39 (2001–2003)	1. FEV1, FVC, FRC, RV, TLCO		
2005''	2. Treatment-related inclusion criteria: no restriction to	2. Threshold for pathological parameters=FEV1, FVC, FRC, RV,		
	cancer diagnosis, allogeneic HSC I	Obstructive EEV1/EVC < 80% predicted		
	5. Exposure/PICO: Cyclophosphalmide 100%, 1BI or thomasachdominal imadiation 70% busulfan 15%	Destrictive=FEVI/FVC < 80% pred		
	thoracoaddoniinar irradiadon 79%, busunan 15%	Diffusion conscitution province in the second secon		
Zorzi et al I Dediatr	$1 \text{ N} - 1/3 (1007 \ 2010)$	1 EVC TIC BV DICO		
Hematol Oncol 2015 ⁴⁵	 N=145 (1997-2010) Treatment related inclusion criteria: Hodgkin 	2. Threshold for nothological parameters-TLC < 80% pred EVC		
Tiemator Oficol, 2015	lymphoma_extracranial_germ cell tumors	2. The shou for pathological parameters = 1 Le < 80% pred, 1 ve		
	3 Exposure/PICO: Bleomycin 100%: radiotherapy 60%	Obstructive-abnormal FVC normal TLC and RV/TLC >-30%		
	smoking 2%	and scooped flow-volume loop		
	č	Restrictive=reference to Pellegrino et al		

Abbreviations: ABVD, adriamycin, bleomycin, vinblastine, dacarbazine; COP, cyclophosphamide, vincristine, prednisone; DLCO, diffusion capacity for carbon monoxide; FVC, forced vital capacity; HSCT, hematopoietic stem cell transplantation; MIP, maximum inspiratory pressure; MEP, maximum expiratory pressure; n, number; PFT, pulmonary function testing; pred., predicted; SD, standard deviation; SCT, stem cell transplantation; TBI, total body irradiation; TLC, total lung capacity.

		Obstructive*	Restrictive *	Hyperinflation*	Diffusion capacity*
	Yes/no	= Very low ³¹	= Very low ³¹	\uparrow Very low ³¹	No study
	Age	\uparrow Low ^{32,33}	= Very low ^{33,37}	NS	\uparrow Very low ^{32,33,34}
HSCT	GvHD	\uparrow Very low ^{35,36}	↑ Very low ³⁵	NS	\uparrow Low ³⁴
	Infection	NS	NS	NS	NS
	TBI	= Very low ^{34,36}	↑ Very low ^{34,36}	NS	↑ Moderate ³⁴
	Yes/no	\uparrow Very low ⁴⁶	\uparrow Very low ^{1,46}	NS	= Low ¹
Cyclophosphamide	Higher dose	= Very low ^(Green 2015)	↑ Very low ^(Green 1998)	NS	NS
	Age	NS	NS	NS	NS
	Yes/no	NS	NS	NS	NS
Methotrexate	Higher dose	NS	= Very low ⁴²	NS	NS
	Age	NS	NS	NS	NS
Gemcitabine		NS	NS	NS	NS
	Yes/no	\downarrow Very low ^{31,38,39}	=Very low ^{1,2,31,38,39}	\downarrow Very low ^{31,38}	= Very low ^{1,2,38,39}
Bleomycin	Higher dose	=Very low ³¹	↑ Very low ³¹	= Very low ³¹	= Very low ^{45,49,53}
	Age	NS	NS	NS	NS
	Yes/no	NS	= Very low ²	NS	= Very low ²
Busulfan	Higher dose	NS	NS	NS	NS
	Age	NS	NS	NS	NS
	Yes/no	NS	= Very low ²	No study	= Very low ²
Nitrosourea	Higher dose	NS	NS	NS	NS
	Age	NS	NS	NS	NS
	Yes/no	\uparrow Very low ^{31,40,46,51,52}	\uparrow Very low ^{1,31,40,46,51,52}	\uparrow Very low ^{31,51,52}	$\uparrow \text{Very} \\ \log^{1,40,454,46,51,52}$
D - 12 - 41	Higher dose	\uparrow Very low ^{3,38,50}	↑ Very low ^{2,3,38,47,50}	\uparrow Very low ³⁸	↑ Very low ^{2,3,38,47,50}
кашошегару	Field	NS	NS	NS	NS
	Age	= Very low ^{38,48,50}	= Very low ^{38,48,50}	= Very low ³⁸	= Very low ^{38,48,50}
	Radiosensitizer	NS	NS	NS	NS

Table 2: Conclusions and quality of the evidence for the risk and risk factors for pulmonary function impairment among childhood, adolescent, and young adult cancer survivors diagnosed up to age 30.

	Yes/no	↑ Very low ^{31,38,39,40}	\uparrow Very low ^{1,31,38,39,40}	= Very low ^{31,38}	= Very low ^{1,38,39,40}
Surgery	Resection	NS	NS	NS	NS
	volume				
	Age	NS	NS	NS	NS
Combinations	Surgery and chemotherapy	NS	No case in bleomycin plus surgery arm (bleomycin only as reference) ¹	NS	= Very low ¹
	Surgery and radiotherapy	= Very low ⁴⁰	= Very low ^{1,40}	NS	\uparrow Very low ^{1,40}
	Radiotherapy and chemotherapy	\downarrow Very low ⁴¹	= Very low ^{1,41}	NS	↑ Very low ^{1,41}
Smoking	Yes/no	= Very low ⁴⁰	= Very low ⁴⁰	NS	= Very low ⁴⁰
	(Ex-)smoker vs. smoker	↑ Very low ⁴³	= Very low ^{2,41,43}	NS	= Very low ^{2,43,44,45}
	Higher dose	NS	NS	NS	NS
	(pack years)				
	Environmental	NS	NS	NS	NS
	exposure				
	Cannabis	NS	NS	NS	NS

Explanation for categorisation of risk factors: \uparrow increased risk; \downarrow decreased risk; = no increased risk, inconsistent or not significant findings. GvHD, Graft versus Host Disease; TBI, Total Body Irradiation; HSCT, Haematopoietic Stem Cell Transplantation; NS, No Study. *Categorisation of pulmonary function parameters by publication in Table 1

Table 3: Main reasons for downgrading the quality of evidence

Representativeness uncertain:			
- 13	studies (50%) did not report original cohort sizes from where populations at-risk		
W	ere selected (selection and attrition biases).		
Imprecision and indirectness in performing PFT:			
- Oi	nly 15 of 27 included studies (56%) used ERS/ATS recommendations on how to		
pe	rform PFT.		
Imprecision and indirectness in reporting PFT results:			
- Oi	nly 20 of 27 studies (74%) reported the source of reference values used to standardise		
th	e survivor results. 22 different sources of reference values were used overall, with up		
to	10 different sources of reference values in the same study.		
- Oi	nly 2 of 27 studies (7%) used the reference values from the global lung initiative,		
w	hich is established as the international standard.		
Inconsistent reporting of PFT results:			
- 20) of 27 studies reported percentage of predicted values		
- 5	of 27 studies reported z-scores		
- 1	of 27 studies reported percentage of predicted values and z-scores		
- 1	of 27 studies reported percentage of predicted and absolute values		

Inconsistent definitions of cut-off values used to define normal values, obstruction, restriction, or diffusion capacity impairment

Abbreviations: ATS, American Thoracic Society; ERS, European Respiratory Society; PFS, pulmonary function testing

 Table 4: Harmonised recommendations for surveillance of pulmonary dysfunction for childhood, adolescent, and young adult cancer survivors.

General recommendations

CAYA cancer survivors and their healthcare providers should be aware of the risk of reduced pulmonary function, and pay attention to symptoms (shortness of breath on exertion, chronic cough) after treatment with:

- Allogeneic haematopoietic stem cell transplantation (very low quality of evidence)
- Radiotherapy to fields exposing lung tissue, including TBI (very low to moderate quality of evidence)
- Surgery to the lung or chest wall (very low quality of evidence)

(strong recommendation)

In at-risk* CAYA cancer survivors it is recommended to:

- Get a yearly influenza vaccination and additional vaccinations based on local or national recommendations
- Consider vaccination against viral pathogens that cause pneumonias according to local or national guidelines

For all CAYA cancer survivors it is recommended to:

- Avoid tobacco exposure, quit smoking, and/or reduce exposure to environmental smoke (strong recommendation, expert opinion)

Who needs surveillance for pulmonary dysfunction and what surveillance modality should be used?

Routine pulmonary function testing is not recommended for <u>asymptomatic</u> at-risk* CAYA cancer survivors, due to lack of interventions to prevent the deterioration of asymptomatic pulmonary dysfunction (strong recommendation, lack of evidence, expert opinion)

*Survivors treated with allogeneic haematopoietic stem cell transplantation (very low quality of evidence); radiotherapy to fields exposing lung tissue, including TBI (very low to moderate quality of evidence); and surgery to the lung or chest wall (very low quality of evidence)

Abbreviations: CAYA, childhood adolescent and young adult; TBI, total body irradiation

Table 5: Gaps in knowledge and future directions for research

Current knowledge gaps

Risk factors for symptomatic and asymptomatic pulmonary dysfunction among CAYA cancer survivors, including therapeutic exposures, medical conditions, and environmental exposures.

- Treatment with
 - chemotherapeutic agents with reported pulmonary toxicity according to current LTFU guidelines, such as bleomycin, busulfan, carmustine, lomustine
 - chemotherapeutic agents without reported pulmonary toxicity according to current LTFU guidelines and without clear evidence, such as cyclophosphamide, methotrexate
 - targeted agents, such as tyrosine kinase inhibitors, checkpoint inhibitors, and monoclonal antibodies
 - immunotherapy, such as chimeric antigen receptor T-cell therapy
 - thoracic radiotherapy, such as proton versus photon therapy, and increasing radiation doses or volumes
 - thoracic surgery, such as thoracotomy and pneumonectomy
 - haematopoietic stem cell transplantation
 - combination of the above-mentioned treatment modalities
 - combination of bleomycin with additional oxygen (during anaesthesia)
- Impact of time from exposure on pulmonary function
- Impact of age at exposure on the risk of developing pulmonary dysfunction
- Impact of attained age at screening on outcome measures, such as PFT results, and clinical symptoms
- Impact of existing co-morbidities on pulmonary function, such as cardiac disease, impaired immune function, and neurological deficits
- Impact of genetic variants on pulmonary toxicity of cancer treatments
- Impact of acute treatment-related toxicities on pulmonary function, such as pulmonary infections, pulmonary GvHD
- Impact of inhaled substances, such as vaping, medicinal cannabis, alone or in combination with smoking cigarettes (during therapy and post-therapy)

Detection of pulmonary dysfunction among CAYA cancer survivors

- Benefit of novel PFT, such as multiple-breath washout tests, exhaled nitric oxide, impulse oscillometry, and lung imaging (MRI), including acceptability, sensitivity, specificity, practical consequences, and costs
- Longitudinal course of pulmonary dysfunction after cancer treatments, including onset and progression, to determine intervals for PFT
- Effects of the cancer itself and cancer treatments on physiological processes, including lung growth, peak attained lung function, and functional decline with ageing
- Association of functional outcomes (from PFT detected by screening) with clinical symptoms (onset, type, and severity)
- Predictive value of serial PFT to identify individuals who will develop pulmonary dysfunction in the future and who will become symptomatic
- Predictive value of serial lung function tests with relation to termination of screening (normal or stable results)
- Cost-effectiveness of different screening frequencies and modalities
- Potential harms associated with excessive screening and false-positive findings

Interventions to prevent, reverse, or slow the decline in pulmonary function

- Effect of variation in cancer treatments, such as radiotherapy, chemotherapy, or surgery on pulmonary dysfunction
- Effect of lifestyle and other preventive strategies on development or worsening of pulmonary dysfunction, such as lifestyle counselling and physical activity
- Effect of interventions, such as medical treatments and physiotherapy, to improve or reverse pulmonary dysfunction
- Benefit of optimal management of co-morbidities, such as cardiac dysfunction and chronic immunosuppression, on pulmonary dysfunction and pulmonary symptoms
- Effect of therapeutic targets used for other pulmonary diseases, such as antifibrotic drugs

Factors to be considered in future studies assessing the risk of pulmonary dysfunction among CAYA cancer survivors

• Close collaboration between oncologists and pulmonologists; paediatric and adult experts.

Study design

- Need for sufficient numbers of CAYA cancer survivors undergoing PFT to maximise statistical power and allow stratifying analyses into sub-groups
- Collaboration between different study groups working with harmonised protocols
- Avoidance of selection or attrition bias among study cohorts, by testing independent of pulmonary symptoms; access to testing independent of socioeconomic factors etc
- Longitudinal investigations including baseline before starting treatment and serial assessment of pulmonary function and correlation with symptoms and other patient-reported outcomes

Standardisation of PFT

- Performance of PFT by trained personnel in centres with expertise / accredited centres
- Performance of PFT according to standardised protocols, such as ERS/ATS guidelines
- Interpretation of PFT results according to standardised protocols for quality control, such as ERS/ATS guidelines, and standardised reference values, stratified by age and sex, such as GLI
- Reporting PFT results as raw data and z-scores instead of binary cut-offs, such as normal or abnormal, restrictive, obstructive, or diffusion capacity impairment
- Measurement of different lung function parameters to better describe the nature of lung function impairment
- Using novel PFT to facilitate detection of pulmonary dysfunction

Abbreviations: ATS, American Thoracic Society; CAYA, childhood adolescent and young adult; ERS, European Respiratory Society; GvHD, Graft versus Host Disease; GLI, Global Lung Initiative; MRI, magnetic resonance imaging; LTFU, long-term follow-up; PFT, pulmonary function testing